Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing
By Isabelle Yr Carlsson and Maggie Fick COPENHAGEN/LONDON (Reuters) – Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday. Construction of the plant at Novo’s existing main U.S. manufacturing site in Clayton, North Carolina, will be completed between 2027 and 2029, and will add 1,000 workers to the 2,500 already employed there, … Read more…